According to the latest report by IMARC Group "Hemophilia Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027", The global hemophilia market reached a value of US$ 10.5 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 20.1 Billion by 2027, exhibiting a CAGR of 11.5% during 2022-2027. Hemophilia is a rare inherited bleeding disorder that hampers the blood clotting ability of the body due to the lack of factor VIII, the blood-clotting protein. It can lead to serious health ailments, such as headaches, anemia, conjunctivitis, stomach aches, and mononucleosis. Hemophilia can be treated through clot-preserving medications, fibrin sealants, desmopressin, and vaccination. There are different lifestyle modifications that can also help in treating hemophilia, such as regular exercise and usage of protective gear to prevent injuries. Request for a free sample copy of this report: https://www.imarcgroup.com/hemophilia-market/requestsample Note: We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report. Market Trends: Numerous initiatives undertaken by the governments of different nations for funding the research and development (R&D) of newer treatment methods are primarily driving the global hemophilia market. The escalating prevalence of hemophilia, rising diagnosis rate and the widespread adoption of prophylactic treatment for hemophilia are propelling the market growth. Furthermore, the rapid establishment welfare organizations, such as the National Hemophilia Foundation (NHF) of the United States (US), and World Federation of Hemophilia (WFH), are creating a positive outlook in the market across the globe. Breakup by Type:
- Hemophilia A
- Hemophilia B
- Hemophilia C
- Others
- On-Demand
- Prophylaxis
- Replacement Therapy
- ITI Therapy
- Gene Therapy
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
- Baxter International Inc.
- Bayer AG
- BioMarin Pharmaceutical Inc.
- CSL Behring (CSL Limited)
- F. Hoffmann-La Roche AG
- Grifols S.A.
- Kedrion S.p.A.
- Novo Nordisk A/S
- Octapharma AG
- Pfizer Inc.
- Sanofi S.A.
- Takeda Pharmaceutical Company Limited.